Live birth or ongoing pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine injection of autologous platelet‐rich plasma changes live birth (or ongoing pregnancy) compared with no intervention (very low certainty).
1 finding from 1 review
Ongoing pregnancy · women undergoing assisted reproduction
It is very uncertain whether intraovarian injection of autologous platelet‐rich plasma changes ongoing pregnancy compared with no intervention (very low certainty).
1 finding from 1 review
Miscarriage · women undergoing assisted reproduction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical pregnancy · women undergoing assisted reproduction
It is very uncertain whether intraovarian injection of autologous platelet‐rich plasma changes clinical pregnancy compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events · women undergoing assisted reproduction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Miscarriage · women undergoing assisted reproduction
It is very uncertain whether intrauterine injection of autologous platelet‐rich plasma changes miscarriage compared with no intervention (very low certainty).
1 finding from 1 review
Clinical pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine injection of autologous platelet‐rich plasma changes clinical pregnancy compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events: ectopic pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine injection of autologous platelet‐rich plasma changes adverse events: ectopic pregnancy compared with no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes all‐cause mortality ( compared with control (very low certainty).
1 finding from 1 review
Reduction in pain Various scales including VAS, PISQ; scales ranged from 0 to 4/10/100, where 0 = no pain ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
1 finding from 1 review
Amputation · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes incidence of amputation ( compared with control (very low certainty).
1 finding from 1 review
Angiographic analysis · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Increase in ABI An ABI ratio of 0.9 or less indicates PAD. Values between 0.9 and 1.0 are borderline, and above 1.0 is considered normal ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
1 finding from 1 review
Increase in PFWD (m) ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
1 finding from 1 review
Complications and side effects · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes side effects and complications ( compared with control (very low certainty).
1 finding from 1 review
Adverse events: preterm delivery · women undergoing assisted reproduction
Intrauterine infusion/injection of autologous platelet‐rich plasma may leads to higher adverse events: preterm delivery compared with no intervention or placebo (low certainty).
1 finding from 1 review
Live birth or ongoing pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes live birth (or ongoing pregnancy) compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Miscarriage · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes miscarriage compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Clinical pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes clinical pregnancy compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Adverse event ‐ multiple pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes adverse events: multiple pregnancy compared with no intervention or placebo (very low certainty).
1 finding from 1 review